Journal · Updated 2026-08-11
Flat vs Dose-Tiered Tirzepatide Pricing: The Math Over a Titration Year
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
Tirzepatide pricing comes in two structures, and the difference is worth more than most price gaps between programs. Dose-flat pricing holds one number from the 2.5 mg starter through 15 mg — the structure NexLife, Yucca, Eden, and the other flat programs in our database run. Dose-tiered pricing charges more as the dose climbs — commonly thirty to a hundred dollars a month more at the 10, 12.5, and 15 mg tiers. Because tirzepatide's label is designed to escalate — 2.5 mg for four weeks, then 5, then upward in four-week steps toward a maintenance dose that is usually 10 mg or higher — a typical buyer spends only two or three months of the year at the cheap tiers and the rest at the expensive ones. The arithmetic that follows: a tiered program that undercuts a flat one by fifty dollars at the starter dose commonly costs more by month five and hundreds more across the year. This site ranks at the maintenance dose for exactly this reason, and this page runs the full-year math.
The titration year, month by month
The label's standard escalation puts a new patient at 2.5 mg for weeks one through four, 5 mg for weeks five through eight, and then stepwise increases — 7.5, 10, and for many patients 12.5 or 15 mg — each held at least four weeks, with the pace individualized by tolerability. Translated to a calendar: months one and two live at the starter tiers, month three commonly at 7.5, and months four through twelve at 10 mg or above for the majority of weight-management patients who titrate to effect. That distribution is the whole pricing story. A structure priced to look attractive at 2.5 mg is pricing the two months you pass through; a structure priced flat is pricing the nine months you live in. Any comparison that quotes starter-tier numbers against maintenance numbers — the oldest structural trick in this market's advertising — is comparing a hallway to a house.
The worked year, in words
Take a flat program at three hundred dollars every month: the year totals three thousand six hundred dollars, and the number was knowable on day one. Now take a tiered program that looks cheaper at the door — two hundred fifty dollars at the starter tiers — but adds fifty dollars at 7.5 mg and fifty more from 10 mg up: two months at two fifty, one month at three hundred, and nine months at three fifty totals three thousand nine hundred fifty dollars — three hundred fifty dollars more than the flat program that "cost more" in every advertisement, with the crossover arriving around month five. Push the tier spread to the hundred-dollar-per-step structures our desk has recorded and the gap widens toward seven hundred; hold a patient at 15 mg and it widens again. The only scenarios where tiered wins: a patient who stays at 5 mg or below long-term (a real but minority pattern, usually tolerability-driven), or a short trial run never intended to reach maintenance. If either describes you, the tiered discount is real; if the standard titration describes you, it is a loan against months four through twelve.
Exposing a tier before you pay
Three questions, in writing, before checkout. "Is the monthly price identical at 2.5, 10, and 15 mg — yes or no?" — a structure that needs a paragraph to answer a yes-or-no question has answered it. "What is the exact monthly price at 12.5 mg?" — the tier most programs bury, and the dose many patients actually maintain at. "Does the price shown at checkout apply after titration, and where is that stated in the terms?" — because a screenshot of the answer is what governs later disputes. Our database records each program's dose policy as a field, the head-to-head pages flag flat-versus-tiered mismatches automatically whenever two programs differ, and programs whose tiers are visible only inside the checkout funnel are marked unrankable per methodology §4 — a price you cannot see is not a price. One honest complication: a promotional flat rate with an end date (the current tirzepatide floor is exactly that) is flat-with-an-asterisk; the price-change ledger prints the reversion figures so the year's math uses the number the year will actually charge.
Questions people ask
How much more does a dose-tiered program cost over a year?
In our worked example — a $250 starter tier stepping to $350 at maintenance versus a $300 flat program — the tiered structure costs $350 more across a standard titration year, with the crossover around month five. Wider tier spreads ($100 per step) push the gap toward $700. The tiered program only wins for patients who stay at 5 mg or below.
Why does this site rank at the maintenance dose instead of the starting price?
Because starter pricing lasts one or two months and maintenance pricing lasts the rest of the year. A ranking at the starter dose would systematically favor tiered structures for the exact months buyers pass through fastest — the structural trick this page exists to expose.
Which programs in the database are dose-flat?
The dose-policy field on every provider record answers it, and the head-to-head pages flag the mismatch automatically whenever a flat and a tiered program meet. Check the current database rather than any static list here — structures change, and the record carries capture dates.
Is a flat promotional rate really flat?
Flat across doses, yes; flat across time, only until its published end date. The current all-in tirzepatide floor is a promotional lock-in with an August 31, 2026 end date and a $215 standard card behind it — both figures on the ledger. Budget the year on the reversion unless the program's lock-in terms hold your enrolled rate.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.